EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis

Keishi Sugino iD, Hirotaka Ono, Mikako Saito, Masahiro Ando, Eiyasu Tsuboi

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0305429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Keishi Sugino und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Tsuboi Hospital, Koriyama city, Fukushima, Japan. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Pyridones, Indoles, Antifibrotic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In real-world studies, the rate of discontinuation of nintedanib (NT) varies from 4% to 53%. Switching anti-fibrotic treatment in patients with idiopathic pulmonary fibrosis (IPF) has not been adequately investigated, and data on the tolerability and efficacy of changes in anti-fibrotic treatment is limited in clinical practice.

Objective

To identify factors associated with poor continuation of NT, efficacy and predictors of deterioration after switching from NT to pirfenidone (PFD) in patients with IPF. Subjects and methods One hundred and seventy patients with IPF in whom NT was introduced between April 2017 and March 2022 were included to investigate NT continuation status and the effect of switching to PFD.

Results

A total of 123 patients (72.4%) continued NT for 1 year and had a significantly higher %forced vital capacity (FVC) at NT introduction than those who discontinued within 1 year (80.9% ± 16.3% vs. 71.9% ± 22.1%, P = 0.004). The determinant of poor NT continuation was the high GAP stage. On the other hand, 28 of 36 patients who discontinued NT because of disease progression switched to PFD. Consequently, FVC decline was suppressed before and after the change. The predictor of deterioration after the switch was a lower body mass index.

Conclusions

In patients with IPF, early NT introduction increased continuation rates, and switching to PFD was effective when patients deteriorated despite initial NT treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisPyridonesIndolesAntifibrotic AgentsHumansMaleFemaleAgedVital CapacityMiddle AgedTreatment OutcomeDisease ProgressionDrug SubstitutionAged, 80 and overRetrospective Studies

Substanzen

nintedanibpirfenidonePyridonesIndolesAntifibrotic Agents

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Tsuboi Hospital, Koriyama city, Fukushima, Japan.

ORCID-Profile: Keishi Sugino

Zitieren

APA

Sugino, K., Ono, H., Saito, M., Ando, M., & Tsuboi, E. (2024). Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis. PLOS ONE. https://doi.org/10.1371/journal.pone.0305429

Vancouver

Sugino K, Ono H, Saito M, Ando M, Tsuboi E. Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis. PLOS ONE. 2024. doi:10.1371/journal.pone.0305429

BibTeX
@article{Sugino2024,
  author = {Sugino, Keishi and Ono, Hirotaka and Saito, Mikako and Ando, Masahiro and Tsuboi, Eiyasu},
  title = {Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0305429}
}
Kostenlos starten →